Cagrilintide (AM833)

The downside is dominated by access and durability problems rather than acute danger, which is the opposite of the GLP-1 fatal-signal worry. At the amylin-class level cagrilintide carries no intrinsic catastrophic safety floor: no insulin secretagogue action means no hypoglycemia, and the closely related approved amylin drug pramlintide has a long safety record. The heavier weights come from the fact that it is unapproved and grey-market only, has no cardiovascular outcome trial, and shows class-norm rebound when stopped. The single most exposed group is anyone sourcing it from research-chemical vendors, where contamination and dosing errors are the real hazard. None of those problems are intrinsic to amylin biology; they are circumstantial, tied to where the drug sits in its regulatory life rather than to what it does in the body. That is an important distinction, because it means the downside profile could improve quickly if CagriSema wins approval and a legal supply opens, even though the molecule itself would not have changed at all.

What makes cagrilintide unusual in the grey-market world is that the drug itself is not the scary part. No hypoglycemia, lower nausea, a long safety record for its approved cousin pramlintide. The danger lives in the supply chain and the missing long-term data, not in the molecule's intrinsic biology. Liu 2025, eBioMedicine

Safety Risk (3.5/5.0): Safety risk is better than the GLP-1 drugs at the class level, which is why this scores 3.5 rather than higher. Amylin does not stimulate insulin secretion, so cagrilintide carries minimal hypoglycemia risk, per the receptor work in Liu 2025, and the amylin class lacks the pancreatitis and thyroid signals that shadow the GLP-1 drugs. The approved short-acting amylin analogue pramlintide has years of real-world use behind it. In REDEFINE 1, monotherapy discontinuation due to nausea was about 1 percent, per Garvey 2025. The remaining risk is not intrinsic pharmacology but circumstance: no cardiovascular outcome trial, no long-term human data past 68 weeks, and the genuine hazard of grey-market product quality, which can dwarf the drug's own modest risk profile.

Side Effect Profile (2.6/5.0): Side effects are real but milder than the GLP-1 drugs as monotherapy. Gastrointestinal complaints lead, with dose-dependent nausea in the 20 to 30 percent range, lower than semaglutide, per Lau 2021. The distinctive amylin-class liability is injection-site reactions, which are more frequent than with GLP-1 drugs and call for rotating sites each week. Most gastrointestinal effects are mild to moderate and fade with the slow titration. The combination with semaglutide is a different story, with gastrointestinal events near 80 percent, but that load belongs to CagriSema, not cagrilintide alone.

Financial Cost (3.0/5.0): Cost is moderate. Because cagrilintide is not approved, there is no pharmacy price; grey-market research vials run roughly 150 to 300 dollars each, and a sustained weekly protocol with titration pushes monthly spend into the low hundreds. There is no generic and no insurance pathway, since the drug is investigational. The recurring cost of staying on an unapproved drug, plus the testing needed to verify product quality, is the relevant framing rather than any single vial price.

Time/Effort Burden (2.8/5.0): Effort is moderate. Once-weekly injection is far easier than the two-to-three-times-daily schedule of pramlintide, which is a genuine convenience win. Against that, grey-market material usually needs reconstitution with bacteriostatic water, careful dosing math during the 16-week ramp, cold storage, and weekly site rotation. The weekly cadence keeps the burden lower than daily peptides, but the sourcing and reconstitution overhead is real for anyone outside a clinical trial.

Opportunity Cost (2.4/5.0): Opportunity cost is meaningful because better-evidenced options exist for the same goal. As monotherapy, cagrilintide is outperformed by the approved semaglutide and the dual-agonist tirzepatide, both of which have approval and cardiovascular or large-trial data behind them. The investigational retatrutide reaches even larger weight loss in Phase 2. Spending money and risk on an unapproved single-pathway drug, when its own best use is inside CagriSema, is the core opportunity-cost problem. The honest case for cagrilintide alone is narrow.

Dependency/Withdrawal (3.3/5.0): Dependency risk is low in the addiction sense but real in the functional sense. Cagrilintide does not create a withdrawal syndrome, and it does not suppress a hormonal axis the way some peptides do. What happens when you stop is simpler: appetite returns and weight tends to come back, consistent with the anti-obesity drug class and the satiety mechanism confirmed in Liu 2025. That is reliance on continued dosing to hold the result, not chemical dependence, which is why this scores in the middle rather than at either extreme.

Reversibility (1.8/5.0): Reversibility is excellent, and that is a genuine strength rather than a weakness. When you stop cagrilintide, it clears cleanly with no permanent change to the body, no taper required, and no lasting hormonal disruption. The weight regain that follows is a durability problem, not a reversibility one: the drug itself leaves no footprint once it washes out over a few weeks, consistent with its half-life of about 159 to 195 hours. A low number here means a clean, complete exit, which is exactly what you want from an investigational compound.